AMX-818 is under clinical development by Amunix Operating and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMX-818’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMX-818 overview

AMX-818 is under development for the treatment of HER2 low expressing and EGFR positive solid tumors. It acts by targeting HER2 and CD3. The drug candidate comprises XTEN polypeptide fused HER2 scfv and CD3 scfv linked as a single polypeptide. The drug candidate is a bi-specific monoclonal antibody being developed based on the XPAT (XTENylated Protease-Activated T Cell Engager) platform.

Amunix Operating overview

Amunix Operating (Amunix) is a biotechnology company that discovers and develops long-acting protein-based therapeutics. The company develops protein and peptide therapeutics. Amunix uses its proprietary technology platform XTEN, a proprietary recombinant polypeptide that consists of naturally-occurring hydrophilic amino acids. The company’s product pipeline includes VRS-317, NB1001, NB1002, BIVV-1001, BIVV-1002, AMX-268, and others. Amunix’s develops technologies based on XTEN, a hydrophilic polymer comprised of natural amino acids that can be attached to therapeutic peptides, proteins and small molecules and it offers products for the treatment of hemophilia, diabetes, short bowel syndrome, NASH, Oncology and lipodystrophy. The company partners with biotechnology and pharmaceutical companies. Amunix is headquartered in Mountain View, California, the US..

For a complete picture of AMX-818’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.